Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925733 | 0.87 | ALDH1A1 (0.36) | ALDH1A1MAPTKDM4C | |
| SCHEMBL25925911 | 0.81 | EGFR (0.49) | ESR1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25925862 | 0.79 | MAPT (0.34) | MEN1HSP90AA1KMT2AALDH1A1MAPT | |
| SCHEMBL25925704 | 0.76 | MAPT (0.33) | MEN1HSP90AA1KMT2AATMALDH1A1 | |
| SCHEMBL25925933 | 0.75 | PTGS1 (0.41) | MEN1HSP90AA1KMT2AALDH1A1MAPT | |
| SCHEMBL25925899 | 0.75 | MAPT (0.35) | MEN1HSP90AA1KMT2AALDH1A1MAPT | |
| SCHEMBL25925935 | 0.74 | MPL (0.48) | MEN1HSP90AA1KMT2AALDH1A1MAPT | |
| SCHEMBL18250390 | 0.73 | KMT2A (0.49) | ESR1MEN1HSP90AA1KMT2AALDH1A1 | |
| SCHEMBL25925882 | 0.73 | AHR (0.36) | MEN1HSP90AA1KMT2AATMALDH1A1 | |
| SCHEMBL15049243 | 0.72 | PTGS1 (0.46) | MEN1HSP90AA1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | AR, MAPT, NR5A1 | ESR1 1258/4885MEN1 67/4885HSP90AA1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.